Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we put Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ), which is on the cusp of commercialization, back in the spotlight for the first time in quite some time. The company has a ...

Aldeyra Therapeutics, Inc. (ALDX) announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the signs and symptoms of dry eye disease.With the FDA accepting the resubmitted NDA for review, a decision from the regulatory body is expected on April 2, 2025.Simultaneously, Aldeyra announced that it has expanded its existing option agreement with AbbVie (ABBV) .Shares of Aldeyra were up 11.6% on Nov. 18 fol ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or Oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or Other Ju ...

Olivier Le Moal Thesis Based on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)'s imminent catalysts (Reproxalap), considering the company holds $133 million in cash, cash equivalents and marketable securities, as per March 31st, with a market cap around $230 million, I believe ALDX is still trading at a discount. Hence, in my opinion, Aldeyra offers a high-risk/high-reward investment opportunity, which supports a "Strong Buy" rating for investors with high risk tolerance. In this article, I will be explaining the ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aldeyra Therapeutics, Inc. (ALDX) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aldeyra Therapeutics, Inc. is one of 1048 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Ran ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or Other J ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aldeyra Therapeutics, Inc. (ALDX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aldeyra Therapeutics, Inc. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank g ...

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter frender / iStock via Getty Images Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks. The buyers include renowned billionaire investor Mario Gabelli and French energy giant TotalEnergies.A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a com ...

Aldeyra Therapeutics’(ALDX) clinical-stage immunology pipeline comprises two candidates, reproxalap and ADX-629, which are undergoing late-stage and mid-stage development, respectively.The company’s lead product candidate, Reproxalap, is currently being evaluated in two separate phase III studies for dry eye disease and allergic conjunctivitis.Shares of Aldeyra rallied 43.3% in the past week, driven by the company’s clinical development plan announced on Mar 28, which is intended to enable the resubmission ...